---
title: "Alkermes plc (ALKS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALKS.US.md"
symbol: "ALKS.US"
name: "Alkermes plc"
industry: "Biotechnology"
datetime: "2026-05-20T06:51:28.226Z"
locales:
  - [en](https://longbridge.com/en/quote/ALKS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALKS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALKS.US.md)
---

# Alkermes plc (ALKS.US)

## Company Overview

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.alkermes.com](https://www.alkermes.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.45)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 75 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.21% |  |
| Net Profit YoY | -56.70% |  |
| P/B Ratio | 3.52 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6167004859.00 |  |
| Revenue | 1562300000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.36% | B |
| Profit Margin | 9.78% | B |
| Gross Margin | 87.57% | A |
| Revenue YoY | 3.21% | C |
| Net Profit YoY | -56.70% | D |
| Total Assets YoY | 104.52% | A |
| Net Assets YoY | 15.87% | B |
| Cash Flow Margin | 167.76% | B |
| OCF YoY | 3.21% | C |
| Turnover | 0.49 | C |
| Gearing Ratio | 58.87% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Alkermes plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.21%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-56.70%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.52",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6167004859.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1562300000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.36%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "9.78%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "87.57%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "3.21%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-56.70%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "104.52%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "15.87%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "167.76%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "3.21%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.49",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "58.87%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 40.38 | 51/386 | 19.31 | 14.43 | 13.66 |
| PB | 3.52 | 279/386 | 3.20 | 3.02 | 2.74 |
| PS (TTM) | 3.95 | 89/386 | 3.62 | 3.26 | 3.11 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 65% |
| Overweight | 3 | 18% |
| Hold | 3 | 18% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 37.00 |
| Highest Target | 58.00 |
| Lowest Target | 30.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ALKS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ALKS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ALKS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ALKS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**